(RTTNews) - Emergent BioSolutions Inc. (EBS) announced Wednesday positive two-year persistence data from its Phase 2 clinical study evaluating the safety and immunogenicity of investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback